Skip to main content
x
Norris Cotton Cancer Center
In This Section

Recently Opened Clinical Trials for December 2014

Konstantin Dragnev
Professor
Cancer Mechanism

ECOG
A Phase III double-blind trial for surgically resected early stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein

Alliance-NCI Cooperative Group
Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected Epidermal Growth Factor Receptor (EGFR) mutant Non-Small Cell Lung Cancer (NSCLC)

Alliance-NCI Cooperative Group
Adjuvant lung cancer enrichment marker identification and sequencing trial

Incyte Corporation
A randomized, Phase 2 study of INCB039110 or placebo in combination with docetaxel in subjects with previously treated Stage IIIb, IV, or recurrent non-small cell lung cancer

SWOG
Phase II/III biomarker-driven master protocol for second line therapy of squamous cell lung cancer (screening step)

Eli Lilly, Co.
A randomized Phase 3 study of LY2835219 plus best supportive care versus erlotinib plus best supportive care in patients with Stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapy

Peter Kaufman
Associate Professor
Molecular Therapeutics

PolyPhor Ltd.
A Phase I dose escalation study of POL6326 with eribulin in patients with relapsed, triple negative and hormone refractory ER positive metastatic breast cancer

Frederick Lansigan
Assistant Professor
Molecular Therapeutics

Alliance-NCI Cooperative Group
A randomized Phase Ii trial of ofatumumab and bendamustine vs. ofatumumab, bortezomib (Nsc #681239, Ind #58443) and bendamustine in patients with untreated follicular lymphoma

J Marc Pipas
Professor
Molecular Therapeutics

Incyte Corporation
A randomized, double-blind, Phase 3 study of the JAK1/2 inhibitor, ruxolitinib or placebo in combination with capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first-line chemotherapy (the JANUS 1 study)

0